Clovis Oncology (CLVS) Misses Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall St slumps as sharp tech losses put Nasdaq on course for correction
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts CLVS Hot Sheet
Join SI Premium – FREE
Clovis Oncology (NASDAQ: CLVS) reported Q1 EPS of ($1.54), $0.18 worse than the analyst estimate of ($1.36). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $18.33 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Appian Corporation (APPN) Tops Q3 EPS by 18c; Offers Guidance
- Parker-Hannifin (PH) Tops Q1 EPS by 69c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
